US 12,214,070 B2
Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins
Antoine Decrulle, Paris (FR); and Xavier Duportet, Paris (FR)
Assigned to Eligo Bioscience, Paris (FR)
Filed by Eligo Bioscience, Paris (FR)
Filed on Mar. 17, 2023, as Appl. No. 18/185,696.
Application 18/185,696 is a continuation of application No. 17/698,075, filed on Mar. 18, 2022, granted, now 11,633,348.
Claims priority of provisional application 63/163,077, filed on Mar. 19, 2021.
Prior Publication US 2023/0218505 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 8/99 (2017.01); A61K 35/747 (2015.01); A61K 38/16 (2006.01); A61K 38/47 (2006.01); A61P 17/00 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 8/99 (2013.01) [A61K 35/747 (2013.01); A61K 38/164 (2013.01); A61K 38/47 (2013.01); A61P 17/00 (2018.01); A61Q 19/005 (2013.01); A61Q 19/007 (2013.01)] 15 Claims
 
1. A method for killing unfavorable bacteria on a healthy skin and/or mucosa of a subject, comprising applying on said healthy skin and/or mucosa of said subject an engineered postbiotic composition comprising a microbial lysate and lysostaphin,
wherein said microbial lysate and said lysostaphin have a synergistic effect in killing unfavorable bacteria on said healthy skin and/or mucosa of said subject.